Compound class:
Synthetic organic
Comment: JEDI-852 is the hit molecule from a series of antibacterial compounds that target UDP-2,3-diacylglucosamine hydrolase (LpxH), an enzyme in the lipopolysaccharide synthesis pathway [1]. LpxH is an essential enzyme, conserved in the majority of Gram-negative bacteria but absent in human.
|
|